对比增强超声与磁共振成像评估乳腺癌新辅助化疗后肿瘤反应准确性的比较
这项前瞻性先导研究纳入30例接受新辅助化疗的浸润性乳腺癌患者,于化疗前和化疗后手术前分别行对比增强超声(全氟丙烷脂质微球,10 μL/kg)与增强MRI(钆喷酸葡胺,0.1 mmol/kg),并与手术病理对照。对比增强超声与MRI在基线肿瘤大小上高度一致(r=0.88),化疗后一致性下降(r=0.66);对比增强超声与手术病理肿瘤大小的相关性似乎优于MRI(r=0.75 vs r=0.42)。两者预测病理完全缓解(4例,准确率均为75.0%)和非完全病理缓解(11例,准确率均为72.7%)的效果相当。
要点
- 对比增强超声与MRI在基线肿瘤大小上高度一致(r=0.88,P<.001)。
- 化疗后对比增强超声与MRI肿瘤大小一致性下降(r=0.66,P=.004)。
- 对比增强超声预测病理完全缓解准确率75.0%,与MRI相当。
核心结论
- 对比增强超声是评估新辅助化疗后治疗反应的有价值影像方法,与手术病理乳腺癌大小的相关性似乎与MRI相当。
研究设计与样本
- 前瞻性先导研究,经机构审查委员会批准并符合《健康保险携带和责任法案》,纳入2014年1月至2015年10月30例经乳腺X线摄影或常规超声或两者检出并计划接受新辅助化疗的浸润性乳腺癌患者,于化疗前和化疗后手术前行对比增强超声(全氟丙烷脂质微球,10 μL/kg)和MRI(钆喷酸葡胺,0.1 mmol/kg),并与手术病理对照。
诊断标准与关键数值
- 对比增强超声与MRI基线肿瘤大小中位数均为3.1 cm,Spearman相关r=0.88(P<.001)。
- 新辅助化疗后对比增强超声与MRI肿瘤大小相关r=0.66(P=.004)。
- 对比增强超声与手术病理肿瘤大小相关r=0.75(P<.001),MRI与手术病理相关r=0.42(P=.095)。
- 预测病理完全缓解(4例)准确率对比增强超声与MRI均为75.0%。
- 预测非完全病理缓解(11例)准确率对比增强超声与MRI均为72.7%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This pilot study compared contrast enhanced ultrasound (US) with contrast-enhanced magnetic resonance imaging (MRI) in assessing the treatment response in patients with breast cancer receiving preoperative neoadjuvant chemotherapy (NAC).
METHODS: This prospective Institutional Review Board-approved and Health Insurance Portability and Accountability Act-compliant study included 30 patients, from January 2014 to October 2015, with invasive breast cancer detected by mammography, conventional US imaging, or both and scheduled for NAC. Informed consent was obtained. Contrast-enhanced US (perflutren lipid microspheres, 10 μL/kg) and MRI (gadopentetate dimeglumine, 0.1 mmol/kg) scans were performed at baseline before starting NAC and after completing NAC before surgery. Results of the imaging techniques were compared with each other and with histopathologic findings obtained at surgery using the Spearman correlation. Tumor size and enhancement parameters were compared for 15 patients with contrast-enhanced US, MRI, and surgical pathologic findings.
RESULTS: The median tumor size at baseline was 3.1 cm on both contrast-enhanced US and MRI scans. The Spearman correlation showed strong agreement in tumor size at baseline between contrast-enhanced US and MRI (r = 0.88; P < .001) but less agreement in tumor size after NAC (r = 0.66; P = .004). Trends suggested that contrast-enhanced US (r = 0.75; P < .001) had a better correlation than MRI (r = 0.42; P = .095) with tumor size at surgery. Contrast-enhanced US was as effective as MRI in predicting a complete pathologic response (4 patients; 75.0% accuracy for both) and a non-complete pathologic response (11 patients; 72.7% accuracy for both).
CONCLUSIONS: Contrast enhanced US is a valuable imaging modality for assessing the treatment response in patients receiving NAC and had a comparable correlation as MRI with breast cancer size at surgery.
引用
- Lee SC, Grant E, Sheth P, et al. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer. J Ultrasound Med. 2017. PMID: 28150325. doi:10.7863/ultra.16.05060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。